Baidu
map

内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

AACE2013：糖尿病治疗方案

2013-04-29 晓东 医学论坛网

糖尿病
关注

　　AACE日前公布2013年版《糖尿病综合治疗方案》，方便初级保健医生、内分泌科及其他科室医务工作者更好地预防与治疗糖尿病前期与2型糖尿病。 与糖尿病相关的拓展阅读： Diabetes Care：良好的血糖和血压控制有益于延长糖尿病患者生存期 第一时相胰岛素分泌减少是我国2型糖尿病关键诱因 Diabetic Med：高血压患者治疗时HDL低预示新发糖尿病风险更高 美国糖尿病防

　　AACE日前公布2013年版《糖尿病综合治疗方案》，方便初级保健医生、内分泌科及其他科室医务工作者更好地预防与治疗糖尿病前期与2型糖尿病。

与糖尿病相关的拓展阅读：

原文阅读： AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904922, encodeId=fdd71904922ff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Wed Dec 18 18:56:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989910, encodeId=1eee19899103c, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jul 29 15:56:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699178, encodeId=fc9a16991e871, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Sep 19 08:56:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655670, encodeId=cb9c16556e0d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Nov 20 13:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382988, encodeId=06a213829883a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-12-18 zhangjiqing

    #治疗方案#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1904922, encodeId=fdd71904922ff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Wed Dec 18 18:56:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989910, encodeId=1eee19899103c, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jul 29 15:56:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699178, encodeId=fc9a16991e871, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Sep 19 08:56:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655670, encodeId=cb9c16556e0d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Nov 20 13:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382988, encodeId=06a213829883a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-07-29 zhanglin3079

    #糖尿病治疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1904922, encodeId=fdd71904922ff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Wed Dec 18 18:56:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989910, encodeId=1eee19899103c, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jul 29 15:56:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699178, encodeId=fc9a16991e871, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Sep 19 08:56:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655670, encodeId=cb9c16556e0d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Nov 20 13:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382988, encodeId=06a213829883a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-09-19 zgwhgch

    #AACE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1904922, encodeId=fdd71904922ff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Wed Dec 18 18:56:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989910, encodeId=1eee19899103c, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jul 29 15:56:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699178, encodeId=fc9a16991e871, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Sep 19 08:56:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655670, encodeId=cb9c16556e0d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Nov 20 13:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382988, encodeId=06a213829883a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-11-20 shanyongle

    #ACE#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1904922, encodeId=fdd71904922ff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Wed Dec 18 18:56:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989910, encodeId=1eee19899103c, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jul 29 15:56:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699178, encodeId=fc9a16991e871, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Sep 19 08:56:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655670, encodeId=cb9c16556e0d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Wed Nov 20 13:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382988, encodeId=06a213829883a, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Apr 30 23:56:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-04-30 旅苦化文_208

    #ACE2#

    0

相关资讯

PLoS Med：先兆子痫是糖尿病发病危险因素

　　加拿大一项研究表明，对于无妊娠期糖尿病（GDM）、有先兆子痫（PEC）和（或）妊娠期高血压（GH）的女性，在随访至产后16.5年时，其糖尿病发生风险增加了2倍。与仅有GDM者相比，同时患有GDM、PEC和（或）GH者的糖尿病发生风险显著增加。该论文4月16日在线发表于《公共科学图书馆·医学》（PLoS Med）杂志。 　　该回顾性研究纳入1994年4月至2008年3月期间在加拿大安

Diabetes Res Clin Pract：台北双和医院林俊佃等发现**时相胰岛素分泌是2型糖尿病的触发因素

为了评估在中国人群中，胰岛素敏感性（S1）以及第一（1st ISEC）和第二时相胰岛素分泌（2nd ISEC）在2型糖尿病发展中的相对重要性，来自台湾台北医学大学医学院双和医院的林俊佃教授及其团队进行了一项研究（Beta-cell function and insulin sensitivity at various degrees of glucose tolerance in Chinese

NEJM：糖尿病治疗有进展但仍存不足

　　《新英格兰医学杂志》4月25日在线发表的一项研究显示，自1999年以来，成人糖尿病治疗在依从预防措施和控制糖尿病并发症危险因素方面取得了明显进展。然而，仍有半数的患者未达到血糖控制、血压和血脂控制目标，并且半数患者表示未接受过糖尿病教育、常被忽视而未接受推荐的每年1次的疫苗接种、牙科检查和眼部检查(N. Engl. J. Med. 2013;368:16

Diabetes Care：ADA与ENDO低血糖共识

  　　低血糖对糖尿病患者产生的影响一直以来广受关注，美国糖尿病学会（ADA）和美国内分泌学会（ENDO）对既往与新进证据进行回顾，并于近日公布一份共识文件Hypoglycemia and Diabetes: A Report of aWorkgroup of the American Diabetes Association and The Endocrine Society。 　

NEJM：美国糖尿病防治十年进展回顾

　　近日发表在《新英格兰医学杂志》（NEJM）上的一项研究表明，1999年-2010年美国糖尿病患者降糖达标率提高了8%，将近12%的患者降压达标，21%的患者LDL胆固醇水平降低。然而33%-49%的患者未能降糖达标，每5例糖尿病患者中就有1例未能戒烟。 　　研究主要负责人Mohammed Ali医生表示，全美患者对糖尿病的阻击取得了缓慢而有成效的进展。 与糖尿病相关的拓展阅读：

FDA拟重新审议GSK糖尿病药物文迪雅的安全性

     美国联邦卫生顾问小组将于6月份对葛兰素史克旗下糖尿病药物文迪雅(Avandia)的安全性数据予以重新审议，尽管GSK于近日声称，它已不再寻求使之广泛应用于临床。     010年9月份，美国食品药品管理局（FDA）出于对文迪雅心脏病发作和死亡有关的安全性考虑，对该产品的使用设置了严重限制，只允许文迪雅

Baidu
map
Baidu
map
Baidu
map